Background: The specificity of the aquaporin-4 antibody to predict recurrent inflammatory central nervous system disease has led to the design of the 2015 neuromyelitis optica spectrum disorder criteria which capture all aquaporin-4 antibody seropositive patients. Objective: The purpose of this study was to compare treatment outcomes in aquaporin-4 antibody seropositive patients who met the previous 2006 clinical criteria for neuromyelitis optica with patients who meet the 2015 neuromyelitis optica spectrum disorder criteria. Methods: The study involved a three-center retrospective chart review of clinical outcomes among aquaporin-4 patients diagnosed with neuromyelitis optica and neuromyelitis optica spectrum disorder. Results: Hazard ratios of relapse during immunosuppressive therapy, relative to pre-therapy, were not significantly different for patients who met the 2006 criteria of neuromyelitis optica versus the 2015 neuromyelitis optica spectrum disorder criteria among those treated with azathioprine ( p ¼ 0.24), mycophenolate mofetil ( p ¼ 0.63), or rituximab ( p ¼ 0.97). Conclusion: Reductions in the hazard of relapse during treatment with immunosuppressive therapies, relative to average pre-treatment, were not different for aquaporin-4 antibody seropositive patients categorized using the 2006 criteria of neuromyelitis optica and the 2015 neuromyelitis optica spectrum disorder criteria. These therapeutic findings support the design of the 2015 neuromyelitis optica spectrum disorder criteria which capture all aquaporin-4 antibody seropositive patients.
Introduction
Neuromyelitis optica (NMO) is a rare inflammatory disease that preferentially affects the optic nerves and spinal cord and is distinct from multiple sclerosis (MS). 1, 2 Until recently, NMO diagnosis has been based on application of 1999 or 2006 clinical criteria that each require a history of both optic neuritis (ON) and transverse myelitis (TM). 1, 3 The discovery of the aquaporin-4 antibody (AQP4-IgG), which is highly specific for NMO, 4 facilitated recognition of a wider array of clinical and neuroimaging manifestations that were described by the term neuromyelitis optica spectrum disorder (NMOSD). 3 These findings led to revision of the diagnostic criteria in 2015; the new criteria unify the terms NMO and NMOSD and confer the diagnosis of NMOSD in AQP4-IgG seropositive patients with a wider range of central nervous system (CNS) localization, including the brain and brainstem, even after a single attack. 5 Based on the specificity of AQP4-IgG for prediction of recurrent inflammatory CNS disease, 6 ,7 many clinicians have treated seropositive patients with limited diseases (e.g., a single attack) similarly to those who fulfill 2006 NMO criteria. If limited seropositive NMOSD and historically defined seropositive NMO are indeed the same disease at different clinical stages (i.e., limited NMOSD patients are destined to fulfill 2006 NMO criteria via future clinical attacks) then it would be expected that both NMO and NMOSD seropositive patients, as previously defined, would have similar responses to preventive therapy. There are no approved disease-modifying therapies (DMTs) for NMO or NMOSD, but observational data suggest a positive effect of immunosuppressive treatments, including azathioprine, mycophenolate mofetil, prednisone, and rituximab. 8, 9 The goal of the current study was to validate the clinical relevance of the new diagnostic criteria by comparing the treatment response of historically defined seropositive NMO and limited seropositive NMOSD patients, as defined by the 2015 International Panel for NMO Diagnosis (IPND) criteria. 
Restrictions
In our analysis of relapse reduction during NMO preventive therapies, we define NMO preventive therapies to be azathioprine, mycophenolate mofetil, and rituximab. When analyzing relapse rate reduction during NMO preventive therapy, only the first treatment a patient received using one of the three NMO preventive therapies was included in the analysis. Patients were required to have been treated with azathioprine, mycophenolate mofetil, or rituximab for at least six months. Patients were required to have pre-treatment data, but no minimum pretreatment duration restriction was implemented. Patients who received cyclophosphamide, methotrexate, or mitoxantrone prior to treatment with an NMO preventive therapy were excluded from analysis. Patients who were treated with an MS DMT (interferon b-1a, glatiramer acetate, or natalizumab) prior to treatment with an NMO preventive therapy remained in the analysis. Patients receiving more than one therapy were excluded from analysis, with the exception of concurrent therapy of prednisone with azathioprine or mycophenolate mofetil.
Relapse A relapse was defined as an acute clinical event resulting in a change in neurological examination persisting for more than 24 h localizing to the spinal cord, brain, brainstem, and/or optic nerve not attributable to a pseudoflare of previous relapse. The annualized relapse rate (ARR) was calculated by dividing the number of relapses experienced by the duration of follow-up (in years).
Serological status
The serological status of each patient was determined by each center using commercially available AQP4-IgG tests, including indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and cell-based assays. Patients who tested positive at any time in their disease course were considered seropositive for the purposes of this study.
Analysis
Analysis was performed using SAS software, Version 9.4. Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, North Carolina, USA.
Preliminary Cox proportional hazards models were used to investigate differences in the time to first relapse after the initiation of NMO preventative therapy between the NMO and NMOSD cohorts. A Cox proportional hazards model was fitted with categorical variables corresponding to treatment with azathioprine, mycophenolate mofetil, and rituximab, stratified by diagnosis, while controlling for the squared log time (in years) to the start of treatment after onset, the squared centered and scaled age, and the center at which each patient was seen.
In accordance with our primary objective, an Anderson and Gill (AG) model for recurrent event survival data was fitted to examine reductions in the hazard of relapse during treatment, relative to pretreatment, stratified by the center at which each patient was seen. 10 An additional frailty effect for each patient was incorporated into the model to account for additional within-subject dependence. Time-dependent covariates corresponding to treatment with azathioprine, mycophenolate mofetil, or rituximab were included in the model to examine the effect of each treatment on the hazard of relapse relative to pre-treatment. Two additional timedependent treatment effects were included in the model to capture the additional effect of concurrent treatment with prednisone and azathioprine or mycophenolate mofetil on the hazard ratio of relapse relative to pretreatment. Initially, the time-dependent covariates for each treatment (i.e. azathioprine, mycophenolate mofetil, rituximab, prednisone in addition to azathioprine, and prednisone in addition to mycophenolate mofetil) were stratified by diagnosis and the effect estimates were compared via contrasts based on the asymptotic chi-squared distribution. If the treatment effect estimates were not found to be significantly different between the two diagnoses, the model was refit with common time-dependent treatment effects for the two diagnoses. Additional covariates included in the model were the squared centered and scaled age of patients, a timedependent covariate which is zero during the pretreatment period and one during treatment, and the squared log of years to treatment during the treatment period. The functional forms of age and years to treatment were chosen because they provided superior fit to the observed data.
Secondary exploratory analyses were performed to investigate demographic, clinical, radiological, and disease history differences between seropositive NMO and limited seropositive NMOSD patients. Categorical characteristics were compared between seropositive NMO and limited seropositive NMOSD patient cohorts using Fisher's exact test. Continuous variables were compared between seropositive NMO and limited seropositive NMOSD patient cohorts using a two-sample t-test when necessary assumptions were verified and the Mann-Whitney test otherwise. To compare time to first relapse (in years) between seropositive NMO and limited seropositive NMOSD patient cohorts, survival curves stratified by diagnosis were estimated and compared using the log-rank test. Similarly, survival curves corresponding to time to the initiation of an NMO preventive therapy (in years) stratified by diagnosis were estimated and compared using the Wilcoxon test due to evidence of violations of the proportional hazards assumption. The odds ratio (OR) was calculated to determine the risk of AQP4-IgG seropositive NMOSD to final diagnosis of NMO based on the initiation of an NMO preventive therapy. Due to the exploratory nature of these secondary analyses, p-values were not adjusted for multiple testing.
The significance level was set as a ¼ 0.05 and significance was defined as a p-value <a. The value of P 25 denotes the 25th percentile and P 75 denotes the 75th percentile.
Results
A cohort of 152 aquaporin-4 antibody seropositive patients were initially selected based on their final diagnosis of NMO or NMOSD, representing all patients between 1999-2012 who met inclusion criteria. Diagnosis was reassessed using the 2006 NMO diagnostic criteria and the 2015 IPND NMOSD criteria. 3, 5 Twenty-three additional patients were excluded from further analysis due to incomplete treatment, clinical event, or disease history data. A final total of 129 patients were included in the study, 77 (59.7%) ultimately diagnosed as NMO and 52 (40.3%) ultimately diagnosed as limited seropositive NMOSD. The median follow-up time was six years with a range from seven months to 35 years. Eight patients initially tested AQP4-IgG seronegative but were later confirmed to be seropositive. 
Similar time to first relapse after initiation of preventative therapy
We hypothesized that after the start of an NMO preventative therapy, the survival times to first relapse would not be different between historically defined seropositive NMO and limited seropositive NMOSD patient groups. Figure 1 displays the Kaplan-Meier curves corresponding to the time to first relapse after the initiation of therapy for azathioprine, mycophenolate mofetil, and rituximab, stratified by diagnosis. Figure 2 depicts the occurrence of relapses after the initiation of therapy for historically defined seropositive NMO and limited seropositive NMOSD patients receiving azathioprine, mycophenolate mofetil, and rituximab. For those patients whose first NMO preventative therapy was azathioprine, it was found that the difference in the survivorship function between the two patient groups was not statistically significant ( p ¼ 0.24). Additionally, it was found that the difference in the survivorship function for those patients concurrently treated with azathioprine and prednisone was not significantly different between the historically defined seropositive NMO group and the NMOSD group ( p ¼ 0.71). For those patients whose first NMO preventative therapy was mycophenolate mofetil, it was again found that the difference in the survivorship function between the two patient groups was not statistically significant ( p ¼ 0.63). We were unable to analyze the effect of concurrent treatment of mycophenolate mofetil with prednisone stratified by diagnosis due to the fact that only a single NMO patient received mycophenolate mofetil and prednisone simultaneously. Lastly, for those patients whose first NMO preventative therapy was rituximab, it was again found that the difference in the survivorship function between the two patient groups was not statistically significant ( p ¼ 0.97). 
Similar reductions in ARR in

Discussion
With the identification of the AQP4-IgG as a specific biomarker of NMO came the realization that NMO included a broader phenotypic spectrum than previously appreciated. 6 Thus, many clinicians have treated patients with limited seropositive NMOSD in the same way as they would have treated historically defined NMO patients, with immunosuppressants, such as azathioprine, mycophenolate mofetil, prednisone, and rituximab. 8, 9 Simplification of patient classification and the diagnostic process with the updated 2015 clinical criteria allows for patients with a single clinical event and positive AQP4-IgG antibody test to be diagnosed with NMOSD and therefore begin treatment to try to prevent a second attack. Our multi-center, retrospective review of historically defined seropositive NMO versus limited seropositive NMOSD patients and their treatment history found similar responses with preventive immunotherapy. Specifically, the hazard ratio of the addition of preventive immunotherapy, relative to average pre-treatment ARR, was found to not be significantly different for the two groups. This finding lends evidence to the hypothesis that limited seropositive NMO is the same disease as historically defined NMO but detected at an earlier time point. It also suggests that immunosuppressive treatment at any time point is effective in reducing the odds of conversion to 2006 NMO. These findings also support the unification of the terms NMO and NMOSD within the 2015 IPND revised diagnostic criteria. 5 In this study we found the statistically significant benefit of rituximab and concurrent treatment of azathioprine and prednisone while controlling for a function of the time to the initiation of treatment after onset and a function of age at onset. Additionally, we found a near statistically significant benefit of concurrent treatment of mycophenolate mofetil and prednisone while controlling for a function of the time to the initiation of treatment after onset and a function of age at onset.
Limitations of the current study result from the analysis of retrospective data. Specifically, the patients in each cohort do not represent random samples. Additionally, initiation of a particular treatment was at the discretion of the treating physician and not randomized. Lastly, the sample sizes of patients 
